Wang Lai - BGNE Old Global RD

Insider

Wang Lai is Global RD of BGNE Old
Age 48
Phone345-949-4123
Webhttps://www.beigene.com

Wang Lai Latest Insider Activity

Tracking and analyzing the buying and selling activities of Wang Lai against BGNE Old stock is an integral part of due diligence when investing in BGNE Old. Wang Lai insider activity provides valuable insight into whether BGNE Old is net buyers or sellers over its current business cycle. Note, BGNE Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell BGNE Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

BGNE Old Management Efficiency

The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BGNE Old's management efficiency ratios could be used to measure how well BGNE Old manages its routine affairs as well as how well it operates its assets and liabilities.
BGNE Old currently holds 930.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. BGNE Old has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BGNE Old's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Grant MBAVaxcyte
57
Jenna CohenBlueprint Medicines Corp
N/A
Jingwu MDI Mab
67
Cedric MDApellis Pharmaceuticals
53
Darren GonzalesIonis Pharmaceuticals
N/A
Noah MDTravere Therapeutics
57
Tracie OliverArrowhead Pharmaceuticals
62
Julia ButchkoImmunovant
53
Gigi FengI Mab
43
JD MBABlueprint Medicines Corp
51
Ashish MBAVaxcyte
53
Michael LLMAscendis Pharma AS
54
PharmD JDArrowhead Pharmaceuticals
61
Philip ScalzoBiomarin Pharmaceutical
N/A
JD EsqIonis Pharmaceuticals
71
Javier MDArrowhead Pharmaceuticals
59
Cheng LiI Mab
40
Jerry WangI Mab
N/A
Ivan ZhuI Mab
55
Dr MBABlueprint Medicines Corp
55
Gloria LinKrystal Biotech
N/A
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Beigene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8600 people. BGNE Old (BGNE) is traded on NASDAQ Exchange in USA and employs 10,600 people.

Management Performance

BGNE Old Leadership Team

Elected by the shareholders, the BGNE Old's board of directors comprises two types of representatives: BGNE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGNE. The board's role is to monitor BGNE Old's management team and ensure that shareholders' interests are well served. BGNE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BGNE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
Xiaodong Wang, CoChairman CoFounder
John Oyler, Chairman of the Board, CEO, Founder
Mi Zhou, Director Relations
Liza Heapes, Head Relations
Chan Lee, General VP
Wang Lai, Global RD
Kevin Mannix, VP Relations
Titus Ball, VP Officer
Julia Wang, Executive Officer
Aaron Rosenberg, CFO Officer
Jason Radford, Senior Development
Yang Ji, Chief Officer
Daniel Maller, VP Accounting
Jaspreet MD, Senior Strategy
Diana Francis, VP Compliance
Melika Davis, Clinical Head
Yan Qi, Senior China
Xiaobin Wu, President COO

BGNE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BGNE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in BGNE Stock

If you are still planning to invest in BGNE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BGNE Old's history and understand the potential risks before investing.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like